# US 2025/0082775 A1 · Targeted degradation and removal of amyloid beta plaques for the prevention and treatment of alzheimer’s diseases via engineered nano-scavenger exosomes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082775 A1
- Document ID: US20250082775A1
- Status: Published application
- Kind: A1
- Application number: 18/736,217
- Filed: 2024-06-06
- Published: 2025-03-13
- Earliest claimed: 2023-06-08
- Assignees: Santa Clara University
- Applicants: Santa Clara University
- Inventors: Biao Lu; Renceh Flojo; Joy Ku
- Web page: https://patentgrep.com/patent/US20250082775A1

## CPC

- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6847: {the antibody targeting a hormone or a hormone-releasing or -inhibiting factor}
- C07K 16/18: against material from animals or humans
- C12N 9/6459: {t-plasminogen activator (3.4.21.68), i.e. tPA}
- C12N 9/6462: {u-Plasminogen activator (3.4.21.73), i.e. urokinase}
- C12N 9/6489: {Metalloendopeptidases (3.4.24)}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- C12Y 304/21068: Tissue plasminogen activator (3.4.21.68), i.e. tPA
- C12Y 304/21073: u-Plasminogen activator (3.4.21.73), i.e. urokinase
- C12Y 304/24011: Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
- C12Y 304/24056: Insulysin (3.4.24.56)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Exosome-Based Nano-Scavenger (EBNS) are provided to precisely target and remove Aβ plaques. Leveraging exosomes, natural cell-derived vesicles with tissue-penetrating capabilities, these exosomes were engineered to carry disease targeting antibodies and Aβ-degrading enzymes, clearing Aβ specifically, safely and effectively. EBNS can overcome existing treatment limitations and offer a promising avenue for Alzheimer's Disease therapy.

## Claims

### Claim 1

A genetically engineered nano-scavenger exosome capable of binding and degrading a protein, the genetically engineered nano-scavenger exosome comprising an expression vector with a protein-specific binding moiety, wherein the protein-specific binding moiety is selected from the group consisting of a Single-Chain Fragment Variable (scFv), a Tissue Plasminogen Activator (tPA), Urokinase (UPA), an Insulin-Degrading eEnzyme (IDE), and a Neprilysin (NEP), wherein the protein-specific binding moiety is attached to an exosome, and wherein the protein-specific binding moiety is capable of binding and degrading the protein.

### Claim 2 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the protein-specific binding moiety is selected from the group consisting of SEQ. ID. No.1, SEQ ID. No 2 and SEQ ID No. 3.

### Claim 3 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the expression vector further comprises a signal peptide, wherein the signal peptide is SEQ. ID. No. 4, SEQ. ID. No. 5, SEQ. ID. No. 6, SEQ. ID. No. 7, SEQ. ID. No. 8 and SEQ. ID. No. 9.

### Claim 4 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the expression vector further comprises a hinge sequence, wherein the hinge sequence is SEQ. ID. No. 10.

### Claim 5 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the expression vector further comprises a VSVG-transmembrane helix, wherein the VSVG-transmembrane helix is SEQ. ID. No. 11.

### Claim 6 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the expression vector further comprises an GFP reporter protein, wherein the GFP reporter protein is SEQ. ID. No. 12.

### Claim 7 (depends on 1)

The genetically engineered nano-scavenger exosome as set forth in claim 1, wherein the protein is an amyloid beta (Aβ), a Tau protein, an alpha-synuclein, a huntingtin protein, a prion protein, an amyloid light chain (AL) protein, an amyloid A (AA) protein, a transthretin (TTR), an atrial natriuretic peptide (ANP), an islet amyloid polypeptide (IAPP), a gelsolin, an apolipprotein a-I, an apolopoprotein A-II, a cystatin C, a fibrinogen A alpha-chain, a prolactin, a calcitonin, a keratoepithelin or a blood clot.
